Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New River NRP104 Phase III data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

New River's d-amphetamine prodrug NRP104 showed statistically significant results for primary and secondary endpoints in a Phase III study of children with attention deficit hyperactivity disorder, the firm reports May 23. The study of 285 patients aged six to 12 showed that each of three doses of NRP104 had a significant outcome for the ADHD Rating Scale (primary) and the Conners Parent Rating Scale (p<0.0001), New River said. New River is collaborating with Shire on NRP104; the firms signed a global commercialization deal in January. NRP104 is expected to reach the market by 2006 (1Pharmaceutical Approvals Monthly February 2005, p. 19)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel